Artelo (ARTL) Director Blayney Douglas Receives 136-Share Award

What Happened Blayney Douglas, a director of Artelo Biosciences (ARTL), was granted 136 shares (reported as a derivative acquisition) on July 17, 2026. The grant shows an acquisition price of $0.00 (total $0 reported), indicating a compensatory award rather than a market purchase or sale. This is a grant/award transaction (code A), not an exercise or sale.

Key Details

• Transaction date: July 17, 2026; Filing date: July 21, 2026 (filed within the standard 2-business-day Form 4 window).
• Securities: 136 shares acquired, price reported $0.00 (derivative award).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: Vesting Commencement Date = July 17, 2026. Award vests 100% on the earlier of (i) the one-year anniversary of July 17, 2026 or (ii) the day before the issuer’s next annual stockholders’ meeting, provided the reporting person remains a "Service Provider" per the plan.
• No indication of a 10b5-1 plan, tax-withholding sale, or cashless exercise in this filing.

Context This grant appears to be compensatory (director award) and is subject to time-based vesting rather than immediate free trading. Such awards are common for board compensation and do not, by themselves, indicate insider buying or selling sentiment.